Biopharmaceutical companies explore collaborative opportunities in NETDA

A tour event for portfolio companies of 3E Bioventures Capital was held in the Nantong Economic and Technological Development Area (NETDA) on April 18, aiming to deepen integration between the capital's portfolio projects and Nantong's biopharmaceutical industry resources, accelerating regional industrial clustering and upgrading. 

3E Bioventures Capital is a specialized healthcare investment fund focusing on sectors such as innovative drug R&D, medical devices, clinical diagnostics, and medical services. It has collaborated with Nantong to establish multiple funds‌, with cumulative investments in ‌53 projects‌ amounting to ‌2.77 billion yuan ($379.64 million)‌.

During the event, portfolio companies such as Naxitech, Cellbri, and Iomics expressed strong interest in localized collaboration after gaining insight into NETDA's investment environment and policy incentives.

An aerial view of the Nantong Economic and Technological Development Area (NETDA). [Photo provided to nantong.gov.cn]